tbuckley/cabot-search huggingface dataset:
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) as third- to fourth-line therapy for male germ cell tumors (GCT).
Authors: Andrea Necchi, Nicola Nicolai, Patrizia Giannatempo, Daniele Raggi, Giuseppa Napoli, Mario Catanzaro, Davide Biasoni, Tullio Torelli, Angelo Milani, Silvia Stagni, Luigi Piva, Filippo G. De Braud, Alessandro M. Gianni, Roberto Salvioni
Journal: Journal of Clinical Oncology (2012)

341 Background: Rescue of patients (pts) who fail to be cured following 2–3 chemotherapy (CT) combinations ± high dose CT (HDCT) or who are cisplatin-refractory is still an unmet need. The identification of novel active agents/combinations is a priority. Methods: We reviewed the characteristics of consecutive pts who received TPG combination at our Institution for relapse/progression after 2 or 3 previous platinum-based CT lines. Treatment consisted of the administration of paclitaxel 80 mg/m 2 IV, cisplatin 50 mg/m 2 IV and gemcitabine 800 mg/m 2 IV on days 1 and 8 q3w. Program provided up to 8 administrations of TPG followed by surgery of all resectable masses. Paraffin slides of all cases with residual viable cancer after TPG were retrieved: CD30 staining and somatic mutation analysis by Sequenom OncoCarta Panel v.1.0 were planned. Results: From 04/1999 to 07/2011, 74 pts have been treated with TPG, 64 in 3rd and 10 pts in 4th line. Median age was 32 (20–55), median number of prior CDDP cycles was 7 (4–10), 10 pts (13%) had already received HDCT, 4 pts had primary mediastinal GCT, 42 (57%) were CDDP-refractory/abs refractory, 25 pts (34%) had either liver, bone or brain metastases before TPG. 40% developed G3-4 hematologic and 2 pts G3 renal toxicity, none of them being dose-limiting. No treatment delays have been observed. Median number of administrations was 7 (1–10). 8 complete responses (CR), 28 partial responses with normal markers (PRm-) and 13 incomplete response/stable disease have been recorded, for a major response rate (CR+PRm-) of 49%. 34 pts (46%) underwent post-CT surgery which was radical in 15 cases (44%) and led to 7 pathologic CR. 3-, 6- and 12-month PFS was 68% (95% CI 55–76%), 31% (21–42) and 20% (12–30), respectively. 1-yr PFS after HDCT only was 24% (4–53). 12- and 24-month OS was 46% (34–57) and 26% (16–37), respectively. Median PFS and OS were 5 (1–104) and 12 mos (1–116). Conclusions: TPG combination rates first among salvage therapies for refractory GCT, even after failure of HDCT. Benchmark survival endpoints for trials on new agents/combinations have been set. Results of the biomarker analysis will be available in Feb 2012 and may help to corroborate a window of opportunity for targeted agents in GCT.
Measuring knowledge gained for young breast cancer survivors and co-survivors.
Authors: Lori Atkinson, Michelle Esser, Nirmala Singh, Jean Rowe, Megan McCann, Stacy Lewis, Medha Sutliff
Journal: Journal of Clinical Oncology (2016)

213 Background: Cancer impacts not just the survivor, but those caring for her. Young Survival Coalition (YSC) is the premier global organization dedicated to critical issues in young breast cancer survivors (YBCS) and co-survivors. In 2015, targeted programming was introduced at YSC’s Northeast Regional Symposium. Prior to the event, YSC crafted pre- and post-surveys to measure knowledge gained through the Symposium as an intervention for YBCS and co-survivors. Methods: YSC disseminated pre- and post-event evaluations via online surveys. The pre-survey was sent to registrants (240; 75 completed), and the post-survey was sent to attendees (178; 99 completed). The surveys were designed to measure baseline and increased knowledge in the 4 areas presented at the Symposium: Sex and Intimacy (S&amp;I), Practical Matters (PM), Resiliency and Communication. Questions included demographics, diagnosis, identification as YBCS/co-survivor and baseline knowledge in the 4 areas. Questions in the post-survey followed the same format and measured knowledge gained from the Symposium. Results: In pre-survey data, YBCS and co-survivors most wanted knowledge and resources in S&amp;I and PM. Seventy-five percent reported S&amp;I as a challenge since diagnosis, and 51% stated communication in relationships was difficult. Twenty-two percent felt they did not have the resources they needed to address PM, while 20% felt unsure about what resources they needed. Following the Symposium, 74% felt that they had tools and resources to help in their everyday life as it relates to S&amp;I after the Symposium. Sixty-seven percent reported gaining knowledge they did not have prior to attending. S&amp;I as it relates to YBCS (partnered or single) and rebuilding self-confidence were areas where more information was desired. Seventy-five percent indicated they received information on PM of which they were unaware prior to attending. Follow-up care, financial concerns and career were areas where more information was desired. Conclusions: YBCS and their co-survivors are in need of support and information that is targeted and easily accessible. YSC will continue crafting specific programming for YBCS and co-survivors and measuring the knowledge of both to stay current with their needs.
Impact of financial burden on information and opportunity for cancer (ca) patients' (pts) participation (par) in clinical trials (cts).
Authors: Edith P. Mitchell, Dana Dornsife
Journal: Journal of Clinical Oncology (2016)

166 Background: The degree to which cancer caused financial problems may influence ca pts par in cts and negatively impact quality of life (QoL). Financial burden of cts par, may include finding an appropriate trial, traveling to the trial site, paying for travel, lodging and some medical expenses. The Lazarex Cancer Foundation (LCF) was founded in 2006 with mission to improve care, giving hope, dignity, and life to advanced ca pts by providing assistance with options and costs to cts par, community outreach, and education. LCF developed processes to removing the barriers to cts par by improving equitable access to cancer care, increasing cts enrollment, retention and minority par, and increasing cts referrals. Methods: To determine the extent of benefit of LCF, we conducted a retrospective analysis of LCF beneficiaries participating in cts by reviewing and summarizing the #pts, states and countries of residence, age, type of cancer, location and distance to cts site, type of assistance, and #of advocacy/outreach. Results: From 1/01/2010 – 12/31/2015 1479 pts were assisted; age range 4-86 yrs, median 50-60; 638(43%) male, 790 (53%) female, 51 (3.4%) undeclared. 434 did not give racial/ethnic identity; of 1045, 67 (6.4%) were African American, 108 (10.3%) Hispanic, 38 (3.6) Asian Pacific Islander, other 22 (2.1), and Caucasian 760 (72.7%) –total minority 235 (22.5%). Pts resided in 49 states with largest CA-280, TX-131, MA-119, FL-81. Cts were at 115 sites; 38 NCI CCC, 8 NCI DCC. The most common diagnoses were breast-116, leukemia-87, colorectal-48 and many rare type tumors. The median household income was $75,000. Financial assistance to travel to and living expenses at the cts site was the most frequently identified need. Conclusions: Relieving pts of financial burden allows greater access to and participation in cancer clinical trials. Further research and greater resources are needed to define the patient needs and determine methods to eliminate and remove barriers to enrollment and retention. Future research should investigate coverage thresholds that minimize adverse financial outcomes and identify ca pts at greatest risk for financial toxicity to increase par in cts and enhance QoL.
Prenatal and Early Life Triclosan and Parabens Exposure and Clinical Allergic Outcomes
Authors: Kathleen Lee-Sarwar, Russ Hauser, George T. O'Connor, Megan Sandel, Leonard B. Bacharier, Robert S. Zeiger, Nancy Laranjo, Diane R. Gold, Scott T. Weiss, Augusto A. Litonjua, Jessica Savage
Journal: Journal of Allergy and Clinical Immunology (2017)
Proteomics-based system biology analyses unravel a functional structure with prognostic value
Authors: G. De Velasco, L. Trilla-Fuertes, A. Gámez-Pozo, M. Urbanowicz, G. Ruiz-Ares, J.M. Sepulveda, R. Manneh, B. Homet, I. Otero, P. Celiz, F. Villacampa, L. Paz-Ares, J. Fresno Vara, D. Castellano
Journal: Annals of Oncology (2016)
Autologous Hematopoietic Stem Cell Transplantation in Severe Multiple Sclerosis. The Brazilian Experience with Two Conditioning Regimes: BEAM and High-Dose Cyclophosphamide.
Authors: Julio C Voltarelli, Marina A. Coutinho, Ana Beatriz P.L. Stracieri, Maria Carolina B. Oliveira, Daniela A. Moraes, Fabiano Pieroni, Belinda P. Simoes, George M.N. Barros, Amilton F. Ribeiro, Nelson Hamerschlak, Cesar Leite, Jose Zanis
Journal: Blood (2007)
Co-Existing Serological Immune Responses against RHAMM Might Be a Prerequisite for Strong Cellular Immune Responses of CD8-Positive T Cells in RHAMM-R3 Peptide Vaccination for Patients with Different Hematological Malignancies.
Authors: Jochen Greiner, Susanne Hofmann, Krzysztof Giannopoulos, Markus Rojewski, Anna Babiak, Donald Bunjes, Hartmut Döhner, Anita Schmitt, Michael Schmitt
Journal: Blood (2009)
Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib
Authors: Qian Yu, Anna M Eiring, Matthew S. Zabriskie, Jamshid Khorashad, David J Anderson, Jade A Bryant, Marc M Loriaux, Jeffrey W Tyner, Thomas O'Hare, Michael W. Deininger
Journal: Blood (2011)
Insufficient Evidence of Cimetidine Benefit in Protoporphyria
Authors: Janneke G. Langendonk, J. H. Paul Wilson
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Predictive factors of invasive breast cancer recurrence for patients achieving pCR after neoadjuvant chemotherapy
Authors: Mai Onomura, Yoichi Naito, Masaoki Sasaki, Nobuaki Matsubara, Takahiro Kogawa, Ako Hosono, Yoko Yamada, Kimiyasu Yoneyama, Satoshi Fujii, Hirofumi Mukai
Journal: Annals of Oncology (2016)
136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC
Authors: L. Emens, S. Adams, S. Loi, A. Schneeweiss, H. Rugo, E. Winer, C. Barrios, V. Dieras, J. de la Haba-Rodriguez, L. Gianni, N. Kusuma, S.Y. Chui, P. Schmid
Journal: Annals of Oncology (2016)
Observational study in asthmatics patients after reduction/withdrawal of Omalizumab for good asthma control: real life experience from a Severe Asthma Unit
Authors: Jose Alessandro Bastidas Parlanti, Dorkas M. Márquez, Irina Bobolea, Lys Herraez Herrera, Ismael García Moguel, Consuelo Rodríguez Fernández
Journal: Journal of Allergy and Clinical Immunology (2017)
The Association Between Atherosclerosis and Venous Thrombosis: Results From the Tromsø Study.
Authors: Willem M. Lijfering, Sigrid Braekkan, Erin Mathiesen Hald, Ellisev B Mathiesen, Suzanne C. Cannegieter, Frits R. Rosendaal, John-Bjarne Hansen
Journal: Blood (2012)
Allergenicity and Immunomodulatory Effect of a Depigmented-Polymerized Peanut Extract Tested in a Mouse Model of Peanut Allergy
Authors: Philippe A. Eigenmann, Christophe Frossard, Mayte Gallego, Maria Morales Esteban, Jerónimo Carnés
Journal: Journal of Allergy and Clinical Immunology (2017)
Rates of diagnostic imaging in long-term survivors of young adult malignancies.
Authors: Corinne Daly, David Urbach, Therese A. Stukel, Wayne Deitel, Paul C. Nathan, Lawrence Frank Paszat, Nancy N. Baxter
Journal: Journal of Clinical Oncology (2012)

69 Background: In general, clinical practice guidelines do not recommend the use of diagnostic imaging in long-term surveillance of cancer survivors. Although warranted diagnostic imaging has clinical benefits, the overuse of imaging in cancer survivors may lead to false-positive results, more invasive tests, economic burden and unnecessary radiation exposure. The objective of this study was to determine rates of diagnostic imaging in long-term young adult cancer survivors (YAS) compared to cancer-free controls in Ontario, Canada. Methods: We conducted a population-based retrospective study. Young adults aged 20 to 44 diagnosed with an invasive malignancy between 1992 and 1999 who lived at least 5 years without recurrent disease were identified in the Ontario Cancer Registry. YAS were matched 1:5 to randomly selected cancer-free controls on calendar year of birth, sex, and place of residence. The rate at which YAS received plain radiography, CT, ultrasound and nuclear medicine studies was compared to rates received by controls using Poisson regression. Results: 20,911 survivors and 104,524 controls met our inclusion criteria. YAS received all types of diagnostic imaging at significantly higher rates than controls in the 10 year period after 5-year recurrence-free survival. YAS received CT scanning at a rate 3.6-fold higher than controls (95% confidence interval [CI]: 3.37, 3.62). In contract, the difference in rates of ultrasound between the two groups was more modest (rate ratio [RR] = 1.40, 95% CI: 1.38, 1.43). YAS also received plain radiography (RR =1.66, 95% CI: 1.64, 1.69) and nuclear studies (RR=1.97, 95% CI: 1.89, 2.04) at significantly higher rates than controls, resulting in a 4.6-fold adjusted higher diagnostic radiation dose than controls. Conclusions: Survivors received significantly higher rates of all diagnostic studies after 5-year survival compared to their age-matched cancer-free counterparts. Hazards associated with overuse of imaging such as radiation exposure and heightened anxiety about test results need to be considered. Both patients and providers should be educated about the role of diagnostic imaging in long-term surveillance including the utility of studies without radiation, such as ultrasound.
Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma.
Authors: George Somlo, William Bellamy, Todd M. Zimmerman, Paul Frankel, Joe Tuscano, Margaret O’Donnell, Ann Mohrbacher, Stephen Forman, Helen Chen, James Doroshow, David Gandara
Journal: Blood (2005)
STUDIES ON VIRULENCE
Authors: Lloyd D. Felton, Katharine M. Dougherty
Journal: The Journal of Experimental Medicine (1924)

1. A highly virulent strain of pneumococcus, Type I, Neufeld, when grown in an automatic transferring device at 2 hour intervals on different lots of plain broth adjusted respectively to pH = 6.5, 7, 7.5, or 7.8, lost its virulence at a rate in direct ratio to the H ion concentration of the media-the more acid the media, the more rapid the decrease. 2. Growth of a virulent pneumococcus upon plain broth of an H ion concentration changing gradually either to the acid or the alkaline side of neutrality was accompanied by an initial rise in virulence with a subsequent fall, the change being more rapid in the alkaline than in the acid medium. The organism under these conditions underwent an alteration in its behavior toward agglutinating sera; although still specific, its agglutinability became much greater than that of the original organism. This change was more pronounced in the alkaline than in the acid medium. 3. The virulence of a relatively virulent culture of a pneumococcus grown on plain broth underwent different alterations when the organism was transferred at intervals of 1, 2, 4, or 8 hours. With the 1 hour interval, there occurred seemingly an immediate decrease in virulence, while at intervals of 2, 4, and 8 hours, there occurred first a rise and then a fall, the rise being greatest with the 8 hour interval of transfer and least with the 2 hour. 4. Meat infusion adjusted to various H ion concentrations-pH = 7, 7.3, and 7.7-and made with different amounts of meat furnished conditions which caused a decrease in virulence, the unfavorable action varying in inverse proportion to the concentration of the infusion. Dextrose added to both plain broth and to meat infusion neutralized to a marked degree the unfavorable action of these media. 5. The growth of pneumococci on the different ingredients of plain broth, with plain broth made from the same supply as a control, revealed the fact that peptone in 2 per cent solution maintained and even increased the virulence of the strain of pneumococcus studied, while meat infusion caused the usual decrease. The rate of decrease with plain broth was slower than with meat infusion, showing that the 2 per cent peptone neutralized to some extent the unfavorable action of the infusion.
Immunogenicity of 50-Valent Rhinovirus Vaccine
Authors: Sujin Lee, Minh Trang Nguyen, Michael G. Currier, Joe B. Jenkins, Elizabeth A. Strobert, Adriana E. Kajon, Ranjna Madan-Lala, Yury A. Bochkov, James E. Gern, Krishnendu Roy, Xiaoyan Lu, Dean D. Erdman, Paul Spearman, Martin L. Moore
Journal: Journal of Allergy and Clinical Immunology (2017)
OnabotulinumtoxinA vs Sacral Neuromodulation for Urgency Incontinence
Authors: Bertil F. M. Blok
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
5-lipoxygenase and 15-lipoxygenase-2 expression in papillary thyroid carcinoma: Potential therapeutic targets and prognostic markers
Authors: Nicolas T. Kummer, Ismael Reyes, Codrin Iacob, Steve Schaefer, Stimson Schantz, Jan Geliebter
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

3481 

Thyroid cancer has become the most prevalent endocrine malignancy in the US. In the last decade, the incidence has risen 84% and mortality 34% thus making it a significant clinical concern, meriting research in the areas of treatment, detection and prevention. Both clinical and animal studies have correlated high dietary fat intake with an increased incidence of cancer in various tissues. More specifically, studies have implicated polyunsaturated ω-6 fatty acids such as linoleic and arachidonic acids with increased tumor growth. Recent studies show increased leukotriene synthesis, particularly the potent inflammatory chemokines in the 5-lipoxygenase pathway, with the promotion of certain cancers, including breast, lung and prostate. These studies also demonstrated the potential therapeutic effects of lipoxygenase inhibitors in cancer treatment. Additionally, the detection of 15-lipoxygenase in lung cancer is being investigated as a potential prognostic marker. Expression analysis of 7 papillary thyroid tumors vs. paired, normal thyroid tissue, revealed an approximately 5 fold increased in expression of both 5-lox (p = 0.004) and 15-lox-2 (p = 0.09) in all 7 patients. Subsequent down stream enzymes were also elevated in these patients. Thus far, 5-lox expression was validated by real-timer RT-PCR. Increased protein expression of both for 5-lox and 15-lox-2 were observed by western blotting. This is the first time, to our knowledge, that increased activity in the metabolism of arachidonic acid pathway has been demonstrated in papillary thyroid carcinoma, implicating lipoxygenases as a potential therapeutic target and prognostic marker. In addition these data suggest dietary considerations in at risk individuals and patients.
Addressing Physician Burnout
Authors: Tait D. Shanafelt, Lotte N. Dyrbye, Colin P. West
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgeon is investigated over alleged unnecessary operations
Authors: Clare Dyer
Journal: BMJ (2017)

Police are investigating allegations that a consultant orthopaedic surgeon profited from carrying out unnecessary operations on NHS and private patients at a private hospital.

BMI Healthcare’s Fawkham Manor Hospital in Kent withdrew practising privileges from Mohammed Suhaib Sait last July after it was contacted by Kent Police. BMI Healthcare, which has suspended Sait’s admitting privileges at all its hospitals, has commissioned its own independent investigation.

“Kent Police is investigating an allegation of fraud relating to payments made for surgeries carried out at Fawkham Manor Hospital in Manor Lane, Longfield,” the force said. “No arrests have been made and inquiries are ongoing.”

Many of the operations …
Differential Expression Patterns of Apoptotis and Cell Cycle Proteins after Staurosporine Treatment in EHEB (B-CLL) and JURKAT (T-ALL) Cell Lines.
Authors: Dirk Winkler, Daniela Nitsch, Christof Schneider, Annett Habermann, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2004)
Variants in OXA1L Gene Are Associated With Asthma And Atopy in a Latin Population
Authors: Anaque Oliveira Pires, Milca Jesus Silva, Maria Borges Rabelo Santana, Raimon Rios Silva, Hugo Bernardino Ferreira Silva, Norma Vilany Queiroz Carneiro, Gerson Almeida Queiroz, Héllen Freitas Fonseca, Sandro Oliveira Dias, Ryan Santos Costa, Mauricio Lima Barreto, Camila Alexandrina Figueiredo
Journal: Journal of Allergy and Clinical Immunology (2017)